The study aims to evaluate the efficacy and mechanistic impact of semaglutide, a GLP-1 agonist, on newly diagnosed type 1 diabetes patients.<h4>Methods</h4>A retrospective analysis was conducted to assess the effects of semaglutide on individuals with early type 1 diabetes. This evidence concerns the gene GCG and type 1 diabetes mellitus.